Eliquis at $231/Month, Jardiance at $564/Year: What the IRA's $2,000 Cap Actually Saves You on Your 2026 Part D Plan
You take Eliquis for atrial fibrillation and Jardiance for type 2 diabetes. Your neighbor tells you Medicare "fixed" drug costs — no more than $2,000 a year, and Eliquis got a negotiated price. Both of those things are true. What your neighbor probably didn't tell you is that on one 2026 Part D plan, you hit that $2,000 cap in June. On another plan in the same ZIP code, you don't hit it until October. The math in between — how much you're paying out of your checking account every month before the cap kicks in — can differ by several hundred dollars, even though the cap and the negotiated price are identical on paper.
This is the part of the Inflation Reduction Act (IRA) that doesn't make it into the news coverage. The policy changes are real. The Medicare Rights Center's recent rundown of "what's at stake in 2026" is right that before the IRA, there was no hard ceiling on what you could pay for prescriptions in a given year, no government negotiation of drug prices, and no requirement that manufacturers pay rebates when prices outpaced inflation. Those protections now exist. But a national policy floor doesn't erase plan-to-plan variation — it just changes where the variation shows up. Let's walk through exactly where.
What the IRA changed — in plain English
Three provisions matter for your Eliquis-and-Jardiance drug list specifically:
The $2,000 out-of-pocket cap. Once you've personally spent $2,000 on covered Part D drugs in a calendar year (counting deductible, copays, and coinsurance — not premiums), your plan pays 100% of the rest for the year. This replaced the old "coverage gap" or donut hole, where you used to pay a percentage of drug costs even after a certain spending threshold, all the way until you hit a much higher catastrophic limit.
Medicare drug price negotiation. Eliquis is one of the drugs CMS negotiated a lower price for, landing around $231 a month for the negotiated price effective in 2026 — down from a list price that had been well over $500. Jardiance was negotiated too, though its final list-vs-negotiated math varies depending on dose and whether your plan applies it before or after rebates.
Manufacturer inflation rebates. If a drug's price rises faster than inflation, the manufacturer has to pay Medicare back the difference. This doesn't directly change your copay, but it slows the creep in list prices that eventually shows up in your plan's cost-sharing structure.
None of these three provisions tell you which plan to pick. They set the outer boundary. Inside that boundary, your plan's deductible, formulary tier placement for Jardiance, and monthly premium still determine your cash flow for ten or eleven months of the year.
The worked example: same two drugs, two 2026 plans, same $2,000 cap
Here's what that looks like for a reader on Eliquis 5mg twice daily and Jardiance 25mg once daily, comparing two hypothetical but realistic 2026 standalone Part D plans available in the same ZIP code.
| Cost Component | Plan A ($0 premium, $590 deductible) | Plan B ($42/month premium, $0 deductible) |
|---|---|---|
| Annual premium | $0 | $504 |
| Part D deductible | $590 (applies to both drugs before copay kicks in) | $0 |
| Eliquis tier/copay | Tier 3, $47/month after deductible | Tier 2, $10/month |
| Jardiance tier/copay | Tier 3, $95/month after deductible | Tier 3, $65/month |
| Month you hit the $2,000 out-of-pocket cap | Month 9 (September) | Month 6 (June) |
| Total out-of-pocket cash paid through the year | $2,000 | $2,000 |
| Total annual cost (premium + out-of-pocket) | $2,000 | $2,504 |
Both plans cap your out-of-pocket drug spending at exactly $2,000 — that's the IRA's floor, working as designed. But Plan B's $504 annual premium pushes your all-in annual cost $504 higher than Plan A, even though Plan B gets you to the cap three months sooner and gives you cheaper monthly copays along the way. If cash flow matters more to you than the annual total — say, you're managing a fixed monthly budget — Plan B's lower, steadier copays might still be worth the higher total cost. If you're optimizing for the lowest number on the bottom line, Plan A wins by $504.
This is the exact kind of trade-off Medicare Plan Finder doesn't summarize well, and it's the kind of analysis Pelandri runs for you automatically — plugging in your actual drug list, dosages, and pharmacy to show the month-by-month cash flow, not just the annual premium.
Why the negotiated price didn't erase the difference
It's worth sitting with why a negotiated $231 Eliquis price doesn't make every plan identical. The negotiated price is the ceiling on what the drug costs the plan and, indirectly, you. But your copay is set by the plan's formulary tier placement, not by the negotiated price directly. A plan that places Eliquis on Tier 2 (preferred brand) will charge you less per month than a plan that keeps it on Tier 3 (non-preferred brand), even if both plans are paying the same negotiated wholesale price behind the scenes. We covered this exact mechanic in Eliquis Is Now a Negotiated Medicare Drug at $231/Month: Which Part D Plan Costs You Less in 2026? — the negotiated price narrows the gap between plans, but it doesn't close it.
The same logic applies to Jardiance. If you want the specific IRA-negotiated cost breakdown for that drug alone, see Jardiance Is Now a Negotiated Medicare Drug, which shows a $564-versus-$1,179 spread between two plans carrying the same negotiated drug.
The MA overpayment story matters to your premium, even if you never notice it
Here's where the policy landscape connects to your wallet in a less obvious way. The Committee for a Responsible Federal Budget's recent analysis — flagged by the Medicare Rights Center — projects up to $1 trillion in Medicare Advantage overpayments over the next decade, driven largely by "upcoding" (MA plans documenting patients as sicker than fee-for-service data would suggest, which increases the federal payment the plan receives per enrollee). MedPAC has flagged similar concerns for years and has it on the agenda again for the 2026-2027 meeting cycle.
Why does this matter if you're comparing standalone Part D plans, not Medicare Advantage? Because many people compare their standalone Part D premium against a $0-premium Medicare Advantage plan that bundles in drug coverage, and the MA plan's ability to offer that $0 premium is subsidized in part by the higher federal payments at the center of the overpayment debate. That subsidy can mean richer extra benefits today, but it also means MA drug formularies, prior authorization rules, and step therapy requirements for Eliquis and Jardiance can be stricter than a standalone Part D plan's — because the plan is managing utilization more tightly to protect its margin. If you're weighing a $0-premium MA plan against a standalone Part D plan, the honest comparison isn't premium-versus-premium — it's your total annual drug cost including any prior authorization delays, on your specific formulary. We walked through that comparison directly in Medigap Plan G at $158/Month vs. $0-Premium Medicare Advantage: Which Costs Less in 2026 If You Take Eliquis, Metformin, and Atorvastatin?
Your income level changes this math entirely
If you qualify for Extra Help (the Low-Income Subsidy, or LIS), none of the deductible-versus-premium trade-off above applies to you the same way. Extra Help caps your copays at a few dollars per prescription and eliminates the deductible and coverage gap entirely, which is why Eliquis users with Extra Help often pay under $150 a year total, versus $2,000 for someone paying full standard cost-sharing. We broke down that specific gap in Eliquis Costs $144/Year With Extra Help vs $2,000 Without It. If your income is near the Extra Help threshold, it's worth checking eligibility before you even start comparing plan premiums — it changes which plan variables matter at all.
Politics aside, the enrollment window doesn't wait
KFF Health News' coverage of the toss-up California 22nd District race and the broader midterm attention on healthcare affordability tells you something useful, even setting the politics aside entirely: these protections — the $2,000 cap, drug negotiation, inflation rebates — are the product of a specific law, and their future scope is an active policy question being litigated in elections and in MedPAC's meeting agenda right now. That's genuinely useful context for understanding why your Part D costs might shift again in future years. But it has no bearing on your Open Enrollment decision this year. The $2,000 cap and the negotiated Eliquis and Jardiance prices are locked in for 2026 regardless of who wins any particular House seat. What isn't locked in is which plan you're enrolled in, and whether it's the cheapest one for your specific two drugs, your pharmacy, and your ZIP code.
Run your own numbers before enrollment closes
The math above uses illustrative Plan A and Plan B numbers to show the mechanism — deductible timing, tier placement, and premium trading off against each other even under a shared $2,000 cap. Your real plan options in your real ZIP code will have different deductibles, different tier placements for Eliquis and Jardiance specifically, and possibly different preferred pharmacy networks that change your copay further. You can model this for your specific situation at Pelandri, entering your actual drug list, dosages, and preferred pharmacy to see the full year-by-year cash flow across every plan available to you — not just the premium headline.
The IRA raised the floor for everyone. It didn't flatten the differences between plans. Comparing your specific drug list against this year's Part D options — before the enrollment window closes — is still the only way to know which plan actually saves you money.
Sources
- What’s at Stake in 2026: The Inflation Reduction Act — Medicare Rights Center
- With Midterms Looming, Journalists Consider Measles, Food Recalls, and Obamacare — KFF Medicare
- In Toss-Up House District, Voters Crave Leadership To Fix Broken Healthcare — KFF Medicare
- Evidence of MA Overpayment Continues to Mount — Medicare Rights Center
- MedPAC’s analytic agenda for the 2026-2027 meeting cycle — MedPAC